![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
8MB |
Preview |
PDF (Supplemental Information)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
4MB |
| Item Type: | Article |
|---|---|
| Title: | Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma |
| Creators Name: | Fiori, Agnese, Zimmermann, Karin, Li, Anna, Westermann, Jörg, Anagnostopoulos, Ioannis, Menzel, Lutz, Bunse, Mario, Erdlei, Henry, Jayarajan, Jeyan, Grünschläger, Florian, Ortiz-Aguirre, Juan Pablo, Haas, Simon, Teßmann, Uwe-Jens, Freitag, Jens, Rosenwald, Andreas, Kwak, Larry, Wang, Xiuli, Dong, Zhenyuan, Cha, Soungchul, Reiser, John, Peralta, Eigen, Valamehr, Bahram, Krönke, Jan, Höpken, Uta E. and Rehm, Armin |
| Abstract: | Multiple myeloma treatment has experienced tremendous advances through chimeric antigen receptor (CAR) therapies directed to the B cell maturation antigen (BCMA), but remissions are usually transient. To mitigate the risk of BCMA immune escape, we aimed for a simultaneous targeting of BCMA together with the B cell-activating factor receptor (BAFF-R). Single-cell RNA sequencing discovered increased BAFF-R gene (TNFRSF13C) expression in relapsed and refractory multiple myeloma cases, and it emerged as prognostic marker for long-term complete responses. BAFF-R was expressed in plasma cells at earlier maturation stages compared with BCMA-positive plasma cell phenotypes. Bispecific BAFF-R/ BCMA CARs endowed T cells with cytolytic efficacy against multiple myeloma cell lines and primary multiple myeloma cells. In vivo, the dual CAR compensated for BCMA downregulation when BAFF-R was expressed, preventing the evolution of antigen escape mutants that drive resistance to CAR T cell therapy. Our study proposes BAFF-R as a complementary target antigen suitable to eliminate malignant plasma cells with less advanced differentiation, lack of BCMA, and occurrence in dismal prognosis patients. |
| Keywords: | Adoptive Immunotherapy, B-Cell Activation Factor Receptor, B-Cell Maturation Antigen, Chimeric Antigen Receptors, Multiple Myeloma, Plasma Cells, T-Lymphocytes, Tumor Cell Line, Xenograft Model Antitumor Assays, Animals, Mice |
| Source: | Molecular Therapy |
| ISSN: | 1525-0016 |
| Publisher: | Elsevier / Cell Press |
| Volume: | 34 |
| Number: | 3 |
| Page Range: | 1399-1420 |
| Date: | 4 March 2026 |
| Official Publication: | https://doi.org/10.1016/j.ymthe.2025.12.005 |
| PubMed: | View item in PubMed |
| Related to: |
Repository Staff Only: item control page
